Progeroid syndromes

May 19, 2020

Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy(TM) (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies

Apr 27, 2020

Eiger BioPharmaceuticals Announces EMA Validation of Lonafarnib MAA for Treatment of Progeria and Progeroid Laminopathies

Dec 17, 2019

First-Ever Treatment for Rare, Rapid-Aging Disease Progeria Submitted in New Drug Application to the FDA

Dec 16, 2019

Eiger Initiates Rolling Submission of New Drug Application (NDA) with FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies

Dec 19, 2018

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies

Dec 03, 2018

Eiger BioPharmaceuticals Announces FDA Acceptance of IND Application for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies

Oct 22, 2018

Eiger BioPharmaceuticals Receives FDA Rare Pediatric Disease (RPD) Designation for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies and Plans NDA Filing in 2019

Sep 04, 2018

Eiger Announces Positive Meeting with FDA on Progeria Program

May 16, 2018

Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF)

May 16, 2018

Progeria Research Foundation Announces Collaboration and Supply Agreement with Eiger BioPharmaceuticals